Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $13.21 billion. The enterprise value is $13.08 billion.
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 181.82 million shares outstanding. The number of shares has increased by 16.81% in one year.
| Current Share Class | 181.82M |
| Shares Outstanding | 181.82M |
| Shares Change (YoY) | +16.81% |
| Shares Change (QoQ) | +3.05% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 100.36% |
| Float | 167.23M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 32.76 |
| Forward PS | 27.65 |
| PB Ratio | 45.66 |
| P/TBV Ratio | 111.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 35.97 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 4.59.
| Current Ratio | 5.45 |
| Quick Ratio | 4.99 |
| Debt / Equity | 4.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -29.31% |
| Return on Invested Capital (ROIC) | -37.49% |
| Return on Capital Employed (ROCE) | -45.53% |
| Revenue Per Employee | $286,158 |
| Profits Per Employee | -$718,939 |
| Employee Count | 1,271 |
| Asset Turnover | 0.22 |
| Inventory Turnover | 0.94 |
Taxes
In the past 12 months, Insmed has paid $3.71 million in taxes.
| Income Tax | 3.71M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +193.85% in the last 52 weeks. The beta is 0.84, so Insmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.84 |
| 52-Week Price Change | +193.85% |
| 50-Day Moving Average | 74.32 |
| 200-Day Moving Average | 73.79 |
| Relative Strength Index (RSI) | 52.26 |
| Average Volume (20 Days) | 2,940,680 |
Short Selling Information
The latest short interest is 15.12 million, so 8.32% of the outstanding shares have been sold short.
| Short Interest | 15.12M |
| Short Previous Month | 14.50M |
| Short % of Shares Out | 8.32% |
| Short % of Float | 9.04% |
| Short Ratio (days to cover) | 7.18 |
Income Statement
In the last 12 months, Insmed had revenue of $363.71 million and -$913.77 million in losses. Loss per share was -$5.57.
| Revenue | 363.71M |
| Gross Profit | 277.97M |
| Operating Income | -786.57M |
| Pretax Income | -799.73M |
| Net Income | -913.77M |
| EBITDA | -777.70M |
| EBIT | -786.57M |
| Loss Per Share | -$5.57 |
Full Income StatementBalance Sheet
The company has $1.43 billion in cash and $1.31 billion in debt, giving a net cash position of $123.88 million or $0.68 per share.
| Cash & Cash Equivalents | 1.43B |
| Total Debt | 1.31B |
| Net Cash | 123.88M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 285.38M |
| Book Value Per Share | 1.59 |
| Working Capital | 1.32B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$683.88 million and capital expenditures -$21.92 million, giving a free cash flow of -$705.81 million.
| Operating Cash Flow | -683.88M |
| Capital Expenditures | -21.92M |
| Free Cash Flow | -705.81M |
| FCF Per Share | -$3.88 |
Full Cash Flow StatementMargins
Gross margin is 76.43%, with operating and profit margins of -216.26% and -251.24%.
| Gross Margin | 76.43% |
| Operating Margin | -216.26% |
| Pretax Margin | -250.22% |
| Profit Margin | -251.24% |
| EBITDA Margin | -213.82% |
| EBIT Margin | -216.26% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.81% |
| Shareholder Yield | -16.81% |
| Earnings Yield | -6.92% |
| FCF Yield | -5.34% |
Dividend DetailsAnalyst Forecast
The average price target for Insmed is $95.36, which is 31.28% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $95.36 |
| Price Target Difference | 31.28% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | 66.59% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 0.1:1.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 0.1:1 |
Scores
Insmed has an Altman Z-Score of -0.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.28 |
| Piotroski F-Score | 4 |